The CAR T cell therapy treatment Bristol Myers and Bluebird Bio are developing to treat the blood cancer multiple myeloma got FDA priority review, after earlier rejection; BMY stock rose.

The post Bristol Myers, Bluebird Bio Blood Cancer Treatment Gets FDA Priority Review; BLUE Stock Up appeared first on Investor's Business Daily.